I migliori anni della nostra vita (2005). Il "leggero" lutto di Ernesto Ferrero
in Musarra, Franco; Renard, Marie-France; Van den Bossche, Bart (Eds.) "... noto a chi cresciuto tra noi..." Da una riva all'altra. Studi di lingua e letteratura italiana per Serge Vanvolsem (2014)Detailed reference viewed: 49 (1 ULg)
Migración peruana a Ecuador ¿En espera de una regulación definitiva?
Ramos Ordonez, Maria
Article for general public (2010)
Los flujos migratorios peruanos en el sur del Ecuador se incrementaron a partir de la firma del acuerdo definitivo de paz entre los gobiernos de Ecuador y Perú, en el año 1998, después de más de 50 años ... [more ▼]
Los flujos migratorios peruanos en el sur del Ecuador se incrementaron a partir de la firma del acuerdo definitivo de paz entre los gobiernos de Ecuador y Perú, en el año 1998, después de más de 50 años de diferencias limítrofes entre ambos países. Esto, más la dolarización de la economía ecuatoriana en el año 2000, atrajo la migración de cientos de mujeres y hombres peruanos que cruzaron la frontera nacional en busca de nuevas oportunidades. Estos flujos espontáneos y numerosos también tuvieron desencuentros con el mercado laboral local y con sus vecinos ecuatorianos. El intento gubernamental por regularlos se dio a través de una ley especial creada en diciembre del año 2006, denominada “Acuerdo para regular la situación laboral y migratoria de nacionales de Ecuador y Perú en la región de integración fronteriza ampliada”. Sin embargo, esta política migratoria fronteriza no tuvo el impacto esperado, y hubo inconvenientes para una aprobación definitiva. [less ▲]Detailed reference viewed: 37 (0 ULg)
“Migración y subjetividades de género: rechazo y performances de género en El camino a Ítaca de C. Liscano”
in Amerika (2011), 5Detailed reference viewed: 19 (2 ULg)
Migraine - advances in genetic research and possible link to neurophysiological abnormalities
; ; Schoenen, Jean
in Schweizer Archiv für Neurologie, Neurochirurgie und Psychiatrie = Archives Suisses de Neurologie, Neurochirurgie et de Psychiatrie (2001), 152Detailed reference viewed: 29 (2 ULg)
Migraine - clinical neurophysiology.
; Magis, Delphine ; Schoenen, Jean
in Nappi, G.; Moskowitz, M. (Eds.) Headache (2010)
Central nervous system (CNS) dysfunction is thought to be pivotal in migraine, and could occur at several levels: the brain (the cortex and its connections with subcortical nuclei), the brainstem, and ... [more ▼]
Central nervous system (CNS) dysfunction is thought to be pivotal in migraine, and could occur at several levels: the brain (the cortex and its connections with subcortical nuclei), the brainstem, and even peripheral structures (e.g., trigeminal ganglion and nerve). As it is particularly suited to functional evaluation of various components of the nervous system, neurophysiological testing has become a valuable tool for investigating migraine pathophysiology and the effects of pharmacological treatment. However it has limited value for migraine diagnosis because of a high interindividual variability. In this chapter, we critically review and summarize the available published literature on neurophysiological approaches in migraine, i.e., electroencephalography, evoked and event-related potentials, transcranial magnetic stimulation (TMS), electromyography, and cerebellar testing. The most relevant techniques for understanding migraine pathophysiological mechanisms are highlighted. [less ▲]Detailed reference viewed: 55 (4 ULg)
Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.
; ; Schoenen, Jean et al
in Cephalalgia : An International Journal of Headache (1995), 15(5), 337-57
Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from ... [more ▼]
Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system. The mode of action of this drug in migraine and cluster headache is discussed. On the basis of a detailed review of all published trials and available data from post-marketing studies, the efficacy, safety, tolerability and the place of oral and subcutaneous sumatriptan in the treatment of both conditions are assessed. A number of double-blind clinical trials have demonstrated that sumatriptan 100 mg administered orally is clearly superior to placebo in the acute treatment of migraine headache and achieves significantly greater response rates than ergotamine or aspirin. In other studies, 70 to 80% of patients receiving sumatriptan 6 mg sc experienced relief of migraine headaches by 1 or 2 h after administration, and patients consistently required less rescue medication for unresolved symptoms. Sumatriptan was also effective in relieving associated migraine symptoms like nausea and vomiting. Sumatriptan was equally effective regardless of migraine type or duration of migraine symptoms. Overall, approximately 40% of patients who initially responded to oral or subcutaneous sumatriptan experienced recurrence of their headache usually within 24 h, effectively treated by a further dose of this drug. In 75% of patients with cluster headache treated with sumatriptan 6 mg sc, relief was achieved within 15 min. Based on pooled study data, sumatriptan is generally well tolerated and most adverse events are transient. Adverse events following oral administration include nausea, vomiting, malaise, fatigue and dizziness. With the subcutaneous injection, injection site reactions occur in approximately 30%. Chest syumptoms are reported in 3 to 5% but have been associated with myocardial ischaemia only in rare isolated cases. The recommended dosage of sumatriptan at the onset of migraine symptoms is 100 mg orally or 6 mg subcutaneously. The recommended dosage for cluster headache is 6 mg sumatriptan sc. Sumatriptan must not be given together with vasoconstrictive substances, e.g., ergotamines, or with migraine prophylactics with similar properties, e.g., methysergide. Sumatriptan should not be given during the migraine aura. It is contraindicated in patients with ischaemic heart disease, previous myocardial infarction, Prinzmetal (variant) angina and uncontrolled hypertension. [less ▲]Detailed reference viewed: 31 (0 ULg)
Migraine and serotonin: The quest for the Holy Grail goes on.
in Cephalalgia : An International Journal of Headache (2014), 34(3), 163-164Detailed reference viewed: 14 (1 ULg)
La migraine est-elle un trouble évolutif chronique?
in Migraine Contact (2005), 4Detailed reference viewed: 19 (1 ULg)
Migraine management: current trends and future prospects
in Revue Médicale de Liège (2008)Detailed reference viewed: 32 (6 ULg)
Migraine prevention with a supraorbital transcutaneous stimulator. A randomized controlled trial.
Schoenen, Jean ; ; et al
in Neurology (2013), 80Detailed reference viewed: 108 (3 ULg)
Migraine preventive drugs differentially affect cortical spreading depression in rat.
Bogdanov, Vladimir ; Multon, Sylvie ; Chauvel, Virginie et al
in Neurobiology of Disease (2011), 41(2), 430-5
Cortical spreading depression (CSD) is the most likely cause of the migraine aura. Drugs with distinct pharmacological properties are effective in the preventive treatment of migraine. To test the ... [more ▼]
Cortical spreading depression (CSD) is the most likely cause of the migraine aura. Drugs with distinct pharmacological properties are effective in the preventive treatment of migraine. To test the hypothesis that their common denominator might be suppression of CSD we studied in rats the effect of three drugs used in migraine prevention: lamotrigine which is selectively effective on the aura but not on the headache, valproate and riboflavin which have a non-selective effect. Rats received for 4 weeks daily intraperitoneal injections of one of the three drugs. For valproate and riboflavin we used saline as control, for lamotrigine its vehicle dimethyl sulfoxide. After treatment, cortical spreading depressions were elicited for 2h by occipital KCl application. We measured CSD frequency, its propagation between a posterior (parieto-occipital) and an anterior (frontal) electrode, and number of Fos-immunoreactive nuclei in frontal cortex. Lamotrigine suppressed CSDs by 37% and 60% at posterior and anterior electrodes. Valproate had no effect on posterior CSDs, but reduced anterior ones by 32% and slowed propagation velocity. Riboflavin had no significant effect at neither recording site. Frontal Fos expression was decreased after lamotrigine and valproate, but not after riboflavin. Serum levels of administered drugs were within the range of those usually effective in patients. Our study shows that preventive anti-migraine drugs have differential effects on CSD. Lamotrigine has a marked suppressive effect which correlates with its rather selective action on the migraine aura. Valproate and riboflavin have no effect on the triggering of CSD, although they are effective in migraine without aura. Taken together, these results are compatible with a causal role of CSD in migraine with aura, but not in migraine without aura. [less ▲]Detailed reference viewed: 105 (13 ULg)
Migraine specificities during childhood to adulthood: diagnosis and treatment
; Misson, Jean-Paul
in Acta Neurologica Belgica (2006)Detailed reference viewed: 24 (0 ULg)
Migraines et vertiges, une relation à vous faire tourner la tête
FUMAL, Arnaud ; Schoenen, Jean
in Migraine Contact (2002), 2Detailed reference viewed: 22 (5 ULg)